Quotient Bioresearch has completed a £1.5m expansion at its Fordham, Cambridgeshire site to meet increased demand for immunoassay and cell-based work with biopharmaceuticals and biomarkers.
The UK provider of early stage and specialist drug development services said the building work took place over the summer and included a new bioanalytical facility with a capacity for 30 mass spectrometers and laboratories.
Steve Pleasance, managing director of Bioanalytical Sciences at Quotient, said: ‘Our new facilities at Fordham will assist the continued growth of our services, supporting our customers in taking new and innovative approaches. I’d like to thank all those involved in delivering the project on time and on budget. This is a big step forward for Quotient and we’re all very excited about how it will expand our offering to our clients.’
‘The laboratories at Fordham are one of the world’s most extensive bioanalytical facilities, with services spanning biomarkers, small molecules, biopharmaceuticals and antimicrobials,’ he added.
‘Quotient has built a broad and innovative service portfolio, principally targeted at the early stages of drug development. We look forward to showing off this exciting new facility to our clients.’
